ParaZero Technologies (NASDAQ: PRZO) reflected on a milestone-filled 2025 for its DropAir(TM) Precision Airdrop System, citing defense validation, regulatory approvals, and successful field trials that advanced the technology from battlefield use toward civilian, medical, and humanitarian applications. During the year, DropAir progressed to Phase II development with the Israeli Ministry of Defense, secured multiple Defense Export Control Agency global marketing approvals, completed 50 consecutive successful deployment tests, and demonstrated precision delivery of blood transfusions from 200 meters AGL in a joint trial with Israeli defense and medical institutions. The results validate DropAir ability to deliver critical supplies into hostile or inaccessible environments without landing, positioning the system as a scalable solution for next-generation logistics across military, emergency-response, and commercial markets.
NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://nnw.fm/PRZO
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer